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Abstract  
AIM: To investigate whether maternal intravenous beta-mimetic tocolytic therapy increases the risk of autistic 
spectrum disorders (ASD) and poorer behavioural and developmental outcomes. 
METHOD: Our study is a prospective case-control study among 90 children between 1.5 and three years old. 
Cases (n = 46) were toddlers with betamimetic tocolytic exposure; control group toddlers (n = 44) were tocolytic 
untreated. Treated and untreated groups were also divided into subgroups: term and preterm delivered. The 
gestational age of tocolytic treatment start, the dose and duration of exposure in hours were obtained from 
obstetric medical records. The Brief Infant-Toddler Social and Emotional Assessment (BITSEA), the Modified 
Checklist for Autism in Toddlers (M-CHAT) and the Denver Developmental Screening Test (DDST) tests were 
applied for evaluation of social, emotional problems, autism and developmental disorders.  
RESULTS: Term and preterm born toddlers treated tocolytically in utero didn’t demonstrate a higher risk of 
autistic disorders or poorer behavioural and developmental results than controls. In the preterm group, the earliest 
start of tocolytic treatment was correlated with toddlers lower score of the Competencies Scale (p = 0.009) and a 
higher score of the Problems Scale (p = 0.048). Also, we concluded that preterm membrane rupture was 
associated with higher ASD risk in the untreated group (p = 0.043). 
CONCLUSION: Exposure to betamimetics during pregnancy was not associated with an increased risk of autism, 
behavioural and developmental disorders.  
  
 
 
Introduction 
 
Although the development of new medication 
methods is progressing with time, preterm birth is still 
an important cause of perinatal mortality and morbidity 
in the world [1]. About 50% of childhood neurological 
disorders are due to preterm birth [2]. Beta-
sympathomimetics are commonly applied to postpone 
delivery, but it is also well known that this delaying 
process doesn’t cause an improvement in perinatal 
outcomes [3, 4]. On the other hand, administration of 
antenatal corticosteroids enhance foetal lung maturity 
is associated with a decrease in perinatal morbidity 
and mortality [5]. Thereby, tocolytic therapy could 
prolong pregnancy until the administered 
corticosteroids effect is achieved or patient is 
transported to a tertiary care unit [6]. Widely used 
beta-mimetics could have significant maternal, foetal 
and neonatal side effects [7].  
One of these influences is due to cross the 
placenta and stimulation of b-adrenergic receptors of 
the foetal central nervous system during brain 
development [8-11], which inhibits proliferation and 
increases differentiation of neural cells [12]. The 
inability of foetal and neonatal immature tissues to 
desensitize this beta-mimetic exposure [13] may lead 
to long-term consequences like abnormalities of 
nervous system development [10, 11] and, followed 
by this, neurobehavioral deficiencies: impaired school 
performance, cognitive dysfunction, and psychiatric 
disorders [8, 14]. Recent experiments performed on 
rats found that catecholaminergic activity and 
structural changes in brain tissue, especially in the 
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cerebellum after beta-mimetic exposure, are similar to 
those in the brains of autistic patients [9, 15-17]. Also, 
characteristic imbalance of cardiovascular responses 
inherited in autistic children resembles those in beta-
mimetic exposed rats [18, 19]. Recent animal studies 
support the conclusions of research on humans that 
intrauterine beta-mimetic therapy for preterm delivery 
could cause behavioural, cognitive disorders and 
increased risk of ASD in their offspring [20].  
Our case-control study was designed to 
broaden information about the association between 
tocolytic betamimetic treatment; it’s prolongation, 
doses, maternal and prenatal characteristics and 
adverse neuropsychiatric disorders.  
 
 
Materials and Methods 
 
Ethics 
This study was approved by the local ethics 
committee of Trakya University, Edirne, Turkey 
(Protocol Number 2012/160). Written consent was 
obtained from all patients before they were included in 
the study.  
 
Study design 
Our prospective case-control study follows the 
offspring of mothers exposed to beta 2-adrenergic 
agonist use in pregnancy and untreated control 
groups, who delivered term or preterm. Preterm 
untreated groups include samples admitted to the 
clinic with active labour manifestations and 
consequently no possibility of prolonging the 
pregnancy. Cases and controls were included from 
the cohort of 1.5 to 3-year-old children born at Trakya 
University Obstetrics and Gynaecology Department 
between December 2010 and June 2013; in total 90 
children (48 boys, 42 girls).  
Maternal data were obtained from obstetrical 
records and were comprised of maternal age, 
obstetric history (gravida, parity), gestational age of 
delivery and delivery mode (spontaneous, caesarean 
section). Neonatal birth weight, head circumference, 
body length and Apgar scores were selected from 
neonatal records. Patients with completely available 
data were included in the study. Ritodrine is a beta 2-
adrenergic agonist widely used for tocolysis in Turkey. 
Ritodrine is the generic of Prepare. Only continuous 
intravenous route of administration during second and 
third trimester of pregnancy was included in the study. 
Women in the treated group received intravenous 
Ritodrine in an initial dosage of 0.08 mg/min followed 
by increasing the dose by 0.04 mg/min every 15 
minutes until stoppage of contractions or appearance 
of maternal side effects, with a maximum dosage of 
0.35 mg per minute. The gestational age of pregnancy 
when the Ritodrine was applied, the dosage and 
duration of intravenous tocolysis in hours were used 
to explore the association between maternal exposure 
and potential risks for infants.  
Administration of glucocorticoids for induction 
of lung maturity was registered in both groups. 
Children between the ages of 1.5 to 3 years with the 
following criteria were included: main spoken 
language Turkish; no obvious genetic defect, physical 
handicap or congenital chronic disease. To assess the 
social, emotional problems and competencies of 
children, the validated Turkish version of BITSEA 
(Brief Infant-Toddler Social and Emotional 
Assessment), specially designed for toddlers aged 12 
to 36 months, was used [21].  
The BITSEA has 42 items that combine two 
measuring scales: Problems Scale and Competencies 
Scale. Social, emotional problems are measured by 
the Problems Scale, which includes 31 items 
concerning externalizing (e.g. overactivity, aggression 
and defiance), internalizing (e.g. anxiety and 
depression), dysregulation (e.g. negative emotionality, 
and eating and sleeping problems), atypical behaviour 
and maladaptive behaviour. Social-emotional abilities 
like sustained attention, prosocial peer relations, 
compliance, imitation/play skills, mastery motivation, 
empathy, and social relatedness are covered by 11 
items of the Competence Scale. The clinician rates 
each item on a 3-point scale (0 = not true/rarely, 1 = 
somewhat true/sometimes, 2 = very true/always). A 
parent can complete the BITSEA in approximately 5-7 
minutes independently or 7-10 minutes as part of a 
structured interview [22-24]. To identify children at risk 
of autistic disorders M-CHAT (Modified Checklist for 
Autism in Toddlers) validated for Turkey [25] was 
applied. The M-CHAT is a standardized ASD 
screener, which includes 23 items concerning joint 
attention (proto-declarative pointing, following a point, 
bringing to show), responding to name, interest in 
other children, and imitation [26]. The DDST (Denver 
Developmental Screening Test) was used for the early 
detection of developmental disabilities. DDST 
examines the four areas of development: social 
contact, fine motor skill, gross motor skill and 
language [27].  
Social, demographic and environmental risk 
factors were evaluated systematically through 
structured diagnostic interviews with parents. Family 
size, educational level of parents, single parenthood, 
adoptive parent, the death of a parent, separation 
from mother, maternal mental health, medical 
disorders and nicotine exposure during pregnancy, 
television exposure of toddlers were analysed. 
 
Statistics 
Results were analysed by the Pearson Chi-
Square test, Fisher’s exact test, unpaired Student T-
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test, the nonparametric Mann-Whitney-U-test and 
multivariate analysis of variance (MA-NOVA) with the 
psychosocial risk score as a control variable. A p-
value of less than or equal to 0.05 was considered 
significant. 
 
 
Results 
 
To exclude the possible effect of preterm birth 
on the neuropsychiatric development, children were 
distributed into preterm and term delivered groups. 
Concerning maternal age, gestational week of 
delivery, birth weight, head circumference, body 
length and Apgar scores between treated and 
untreated children in term and preterm groups, there 
was found to be no difference (Table 1).  
Table 1: Maternal and perinatal characteristics of the sample 
 Term Birth (Gest. age ≥ 37 weeks)  Preterm Birth (Gest. age < 37 weeks) 
 
Untreated    
(n = 24) 
Treated  
(n = 22) 
p  
Untreated  
(n = 20) 
Treated 
(n = 24) 
P 
Maternal age (y) 29.8 ± 5.7  27.7 ± 4.8  0.195*  30.1 ± 6.6  27.9 ± 5.9  0.174** 
Gestational weeks 39 ± 1.4  37 ± 8.3  0.553*  31 ± 10.9  28.9 ± 11.6  0.553* 
Birth weight (g) 3022 ± 494  3193 ± 425  0.180**  2427 ± 1001  2178 ± 860  0.255** 
Head circumference (cm) 33.7 ± 1.8  34 ± 1.2  0.286*  31.3 ± 10.9  30 ± 3.9  0.286* 
Body length (cm) 49 ± 0.5  49.7 ± 2.3  0.346*  44.9 ± 5.9  44.9 ± 5.5  0.986* 
Apgar score 1
st
 minute 8.7 ± 0.7  8.9 ± 0.2  0.673**  7.7 ± 1.8  7.6 ± 2  0.882** 
Apgar score 5
th
 minute 9.8 ± 0.4  9.9 ± 0.2  0.333**  9.3 ± 1.1  9.1 ± 1.2  0.783** 
Values presented as Mean ±  SD; *, Unpaired t-test; **, Mann-Whitney U test. 
 
Social, demographic and environmental risk 
factors defined as family size, educational level of 
parents, attending of kindergarten, single parenthood, 
adoptive parent, death of parent, separation from 
mother, maternal mental health, medical disorders 
and nicotine exposure during pregnancy, television 
exposure, maternal infection during pregnancy, 
preterm membrane rupture and delivery mode were 
compared in preterm and term groups with and 
without tocolysis.  
Table 2: Social, demographic and environmental factors 
 Term Birth (Gest. age ≥ 37 weeks) Preterm Birth (Gest. age < 37 weeks)) 
N (%) Untreated    
(n = 24) 
Treated  
(n = 22) 
P Untreated (n 
= 20) 
Treated  
(n = 24) 
P 
Elementary Family 19 (79)  16 (73)  0.869* 13 (6)  15 (63)  1.000* 
Low educational 
level of mother 
12 (50)  12 (55)  0.990* 14 (70)  19 (79)  0.727* 
Low educational 
level of father 
10 (42)  7 (32)  0.700* 12 (60)  14 (58)  1.00* 
Attending 
kindergarten 
0 (0)  2 (9)  0.223 0 (0)  0 (0)  - 
Separation from 
mother 
2 (8)  1 (5)  1.000** 0 (0)  4 (16)  0.114** 
Maternal mental 
disorder during 
pregnancy 
3 (13)  3 (14)  1.000** 6 (30)  3 (13)  0.261** 
Maternal medical 
disorder during 
pregnancy 
7 (29)  8 (36)  0.837* 10 (50)  10 (42)  0.804* 
Maternal nicotine 
exposure during 
pregnancy 
1 (4)  2 (9)  0.600** 15 (75)  19 (79)  1.000** 
Television 
exposure of the 
toddlers 
18 (75)  18 (82)  0.725** 17 (85)  16 (67)  0.294** 
Maternal infection 
during pregnancy 
2 (8)  5 (23)  0.234** 3 (15)  6 (25)  0.477** 
Preterm 
membrane rupture 
0 (0)  1 (5)  0.478** 4 (20)  12 (50)  0.081* 
Cesarean section 16 (67)  12 (55)  0.590* 15 (75)  12 (50)  0.166* 
            
*, Continuity correction; **, Fisher’s exact test. 
 Among the samples, there were no toddlers 
with single parenthood, adoptive parent or deceased 
parent. Concerning other factors, no differences 
between treated and untreated groups were obtained 
(Table 2). 
The same pattern of results was seen in 
tocolytically treated and untreated preterm and term 
children according to psychomotor skills, ASD risk, 
competencies and Problems Scale (Table 3).  
Table 3: Autism risk, psychomotor development, emotional 
problems and competencies in term and preterm children 
exposed to tocolysis and untreated controls 
 
 
Term Birth (Gest. age ≥ 37 weeks)  Preterm Birth (Gest. age < 37 weeks) 
N (%) Untreated   (n 
= 24) 
Treated  
(n = 22) 
P  Untreated   (n 
= 20) 
Treated  
(n = 24) 
P 
Autism risk 5 (20.8) 3 (13.6) 0.702**  6 (30) 4 (16.7) 0.472** 
Psychomotor 
developmental 
disabilities 
 
2 (8.3) 
 
0 (0) 
 
0.490** 
  
3 (15) 
 
4 (16.7) 
 
1.000** 
Mean  ±SD            
Competencies 
scale 
19.54 ± 4.032 20.36 ± 1.293 0.847*  18.85 ± 4.017 19.5 ± 3.464 0.810* 
Problems scale 10.08 ± 5.233 10.95 ± 4.933 0.389*  12.40 ± 5.491 13.21 ± 6.827 0.812* 
           
*, Mann-Whitney U test; **, Fisher’s exact test. 
 
Regarding tocolytic treatment start time, 
dosage or duration of pharmacotherapy no significant 
differences in the risk for ASD, psychomotor skills in 
preterm and term children groups were found (Table 
4).  
Table 4: Risk of ASD and psychomotor development 
disabilities associated with beta 2-adrenergic exposure during 
pregnancy 
 
Without Risk of 
ASD 
With Risk of 
ASD 
p* 
Without 
Psychomotor 
Developmental 
Disabilities 
With 
Psychomotor 
Developmental 
Disabilities 
p 
Beginning of 
tocolysis 
(gestational week) 
31.6 ± 6.4 31.7 ± 3.5 0.842 31.54 ± 6.20 32.20 ± 4.97 0.612 
Duration of 
tocolysis  (hours) 
39.5 ± 53.2 13.9 ± 27.7 0.307 33.35 ± 46.69 59.25 ± 63.82 0.332 
Cumulative dosis 
of tocolysis (gr) 
713.2 ± 474.8 1109.1 ± 926.5 0.426 414.1 ± 581.9 226.7 ± 300.9 0.320 
Values presented as Mean ± SD; *, Mann-Whitney U Test. 
 
In the preterm group, the earliest start of the 
tocolytic treatment is associated with the higher score 
on the Problems Scale. The later the treatment is 
applied, the higher the score of the Competencies 
Scale in preterm born toddlers (Table 5).  
Table 5: Correlation of emotional problems and competencies 
with beta 2-adrenergic exposure during pregnancy 
 Preterm (N = 24)  Term (N = 22) 
 
Competencies 
scale 
Problem scale  
Competencies 
scale 
Problem scale 
r p r P  r p R P 
Beginning of 
tocolysis 
(gestational 
week) 
0.521 0.009** -0.408 0.048***  -0.243 0.275 0.351 0.109 
Duration of 
tocolysis  (hours) 
0.046 0.831 -0.131 0.543  -0.036 0.875 -0.096 0.671 
Cumulative dosis 
of tocolysis (mg) 
0.045 0.0834 0.071 0.741  0.113 0.617 -0.221 0.322 
*, Spearman’s rho; **, Statistically significant p < 0.01; ***,Statistically significant p < 0.05. 
 
We did not detect any statistically significant 
difference between toddlers with and without ASD 
risk, concerning the maternal age, gestational week of 
delivery, birth weight, head circumference and body 
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length. In the tocolytically treated group with the risk of 
ASD, the Apgar score at the 5th minute was 
significantly lower than in the group without risk of 
ASD (Table 6).  
Table 6: Characteristics of treated and untreated samples with 
and without ASD risk 
 Untreated  Treated 
 
 
 
Without Risk of 
ASD 
With Risk of 
ASD 
 
p* 
 
 
Without Risk 
of ASD 
With Risk of 
ASD 
 
P 
Maternal age 30.7 ± 5.8 27.5 ± 6.3 0.175  28.15 ± 5.6 26 ± 3.41 0.365 
Gestational weeks 36.2 ± 3 35.6 ± 3.8 0.593  34.7 ± 4.4 33.5 ± 4.6 0.476 
Birth weight (g) 2785 ± 769.9 2685 ± 946.8 0.759  2696 ± 838.2 2485 ± 973.1 0.625 
Head circumference 
(cm) 
32.8 ± 2.4 32.3 ± 4.3 0.648  32.1 ± 3.4 31.4 ± 4.4 0.783 
Body length 47.3 ± 4.1 47.2 ± 6.5 0.417  47.4 ± 4.6 45.8 ± 6.4 0.634 
Apgar score 1
st
 min 8.7 ± 1.5 8.6 ± 0.8 0.504  8.3 ± 1.6 8.0 ± 1.4 0.118 
Apgar score 5
th
 min 9.5 ± 0.9 9.8 ± 0.4 0.454  9.6 ± 0.8 9.0 ± 1.4 0.045** 
Values presented as Mean ± SD; *, Spearman’s rho; **, Statistically significant p < 0.01; 
***, Statistically significant p<0.05. 
 
In addition to defining the psychosocial and 
environmental influence on ASD risk in treated and 
untreated samples, toddlers with and without risk of 
autism were compared according to their family size, 
educational level of parents, attending kindergarten, 
separation from mother, maternal mental health, 
medical disorders and nicotine exposure during 
pregnancy, television exposure, preterm membrane 
rupture delivery mode. In untreated groups, preterm 
membrane rupture was associated with ASD risk; 
however, in children with tocolytic treatment, maternal 
nicotine exposure during pregnancy was higher in the 
group with the risk of autism (Table 7).  
Table 7: Association of social demographic and environmental 
factors with ASD risk 
 Untreated  Treated 
N (%) 
Without Risk 
of ASD 
With Risk of 
ASD 
P  
Without Risk 
of ASD 
With Risk of 
ASD 
P 
Elementary Family 25 75.8 7 63.6 0.457*  25 64.1 6 85.7 0.399* 
Low educational 
level of mother 
18 54.5 8 72.7 0.480*  26 66.6 5 71.4 1.000* 
Low educational 
level of father 
17 51.5 5 45.5 1.000**  18 46.2 3 42.9 1.000* 
Attending 
kindergarten 
0 0 0 0 -  1 2.6 1 14.3 0.284* 
Separation from 
mother 
0 0 2 18.2 0.058*  4 10.3 1 14.3 1.000* 
Maternal mental 
disorder during 
pregnancy 
5 15.2 4 36.4 0.195*  5 12.8 1 14.3 1.000* 
Maternal medical 
disorder during 
pregnancy 
12 36.4 5 45.5 0.724*  14 35.9 4 57.1 0.407* 
Maternal nicotine 
exposure during 
pregnancy 
5 15.2 1 9.1 1.000*  4 10.3 3 42.9 0.06* 
Television 
exposure of the 
toddlers 
27 81.8 8 72.7 0.669*  27 69.2 7 100 0.165* 
Preterm membrane 
rupture 
1 3 3 27.3 0.043***  0.043 30.8 1 14.3 0.654* 
Cesarean section 22 66.7 9 81.8 0.461*  21 53.8 3 42.9 0.694* 
*, Mann-Whitney U Test; **, Statistically significant p < 0.05. 
 
 
Discussion 
 
Our study is directed at analysing the relation 
between beta-sympathomimetic treatment, time of 
start, duration and dose of tocolytic treatment 
administration and toddler’s risk of autistic spectrum 
disorders, behavioural and developmental outcomes. 
Moreover, it is focused on the possible influence of 
psychosocial risks and comedications like calcium 
channel blockers, magnesium sulphate and 
glucocorticoids on brain development. Unlike previous 
research that follows children with poor 
neurophysiologic and performance including autism 
[14, 28, 29], we selected a random group of patients 
delivered in our clinic during an 18-month period. 
Previous studies have demonstrated an increased risk 
of ASD and educational problems in prematurely born 
infants; however, the role of preterm birth itself could 
not be ignored [30, 31].  
Considering this, we divided patients into 
tocolytically treated and untreated term and preterm 
groups, to compare not only tocolytic but also 
prematurity with risk of ASD, behavioural and 
developmental disabilities. We compared similar 
groups to exclude the obstetric, social, demographic 
and environmental risk factors from influencing the 
outcome. The present study did not find any 
association between tocolytic exposure and 
subsequent development of autistic disorders among 
term and preterm born infants. Also, we consider that 
neither the time of treatment start nor the duration and 
dosage of beta-sympathomimetic exposure is 
correlated with increased risk of ASD. Recent studies 
have demonstrated controversial and inconclusive 
results. Connor at al. [32] found evidence of an 
association between tocolytic exposure and risk of 
autistic disorders in dizygotic twins. Pitzer’s group [14] 
also indicated the impairment of motor skills, cognitive 
and socio-emotional development and a higher rate of 
psychiatric disorders in tocolytic treated term born 
children, whereas, Croen at al. [28] did not indicate 
concordance of autistic disorders and beta-
sympathomimetic treatment in utero.  
Also, we consider that time of treatment start, 
dose and duration of beta-sympathomimetic exposure 
did not affect the risk of psychomotor development in 
both term and preterm groups. However, in the 
preterm group, tocolytic treatment start time affects 
the Competencies Scale score, which reflects the 
socially competent functioning of toddlers and 
Problems Scale, which assesses behavioural types 
like externalizing, internalizing and dysregulation. The 
start of the tocolytic treatment in the earliest weeks of 
gestation is associated with a lower score on the 
Competencies Scale; consequently, it contributes to 
significantly lower levels of competencies. The earlier 
the treatment is applied, the higher the score on the 
Problems Scale in preterm born toddlers. Pitzer at al. 
[14] reported an increased level of social, emotional 
problems in 2-, 4-, 5- and 8-year old children exposed 
to beta-sympathomimetic treatment in utero. But in 
term born group, Polowczyk at al. [33] reported 
significantly higher rates of psychopathology in 
children exposed to tocolysis with beta-
sympathomimetics.  
Furthermore, Hadders-Algra at al. [34] also 
found higher rates of poor school performance in 
children prenatally exposed to the tocolytic treatment. 
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In our study, we examined toddlers between 1.5 and 
three years old, which gave us the possibility of 
diagnosing and treating them at an early stage of 
autistic disability. Also, we also controlled possible 
confounding factors like the psychosocial and 
environmental influence on ASD risk in treated and 
untreated samples. We conclude that preterm 
membrane rupture is associated with higher ASD risk 
in untreated groups; however, in tocolytically treated 
children maternal nicotine exposure during pregnancy 
was concordant with increased autistic disorders risk. 
Moore and colleagues [35] did not find any similarity 
between premature membrane rupture and ASD; 
however, Joseph at al. [36] and Dudova et al. [37] did. 
The literature concerning maternal nicotine exposure 
during pregnancy shows different results: some 
authors demonstrate an association between harmful 
exposure and subsequent autism disorder [38, 39], 
others indicate association close to nil [40-42]. 
However, it is well known that tocolytic maintenance 
treatments do not improve perinatal outcome and 
should not be applied for the management of preterm 
labour in general practice [43]. Ritodrine is still widely 
used in Turkey for more than two days in preterm 
labour treatment. With this in mind, we can conclude 
that further evaluation of maintenance tocolytic 
treatments’ long-term effects are needed, to recognize 
potential harmful effects on offspring.  
Study Limitations: There are some limitations 
in our study. Since our study was conducted in a 
centre which delivers tertiary healthcare service, our 
patients might have a different clinical picture. It arose 
from a single centre and therefore was subject to 
selection bias. The small number of subject is another 
limitation of our study. More extensive and multicenter 
studies are required to fully understand the 
relationship between beta-mimetic exposure on child 
development. 
In conclusion, our study is directed at 
analysing the relation between beta-sympathomimetic 
treatment, time of start, duration and dose of tocolytic 
treatment administration and toddlers risk of ASD, 
behavioural and developmental outcomes. The 
present study did not find any association between 
tocolytic exposure and subsequent development of 
autistic disorders, behavioural or developmental 
disabilities among term and preterm born infants. 
Besides this study consider that neither the time of 
treatment start nor the duration and dosage of beta-
sympathomimetic exposure is correlated with 
increased risk of ASD. Considering that currently 
available data reveals contentious results, further 
thorough research is needed to clarify any possible 
influence of beta-mimetic exposure on child 
development. 
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